18 December 2024NewsAmericasMithu Sherin Director of Intellectual Property ALX Oncology, David Diamond VP & Head of Intellectual Property Capstan Therapeutics, Alexander Trimble Member Mintz, Siegmund Gutman Chair Life Sciences Litigation Practice Mintz

WATCH: Beyond the obvious: novelty, non-obviousness, and the inventive step in polymorph patents and beyond

In the world of intellectual property, securing patents for innovative ideas rests heavily on the criteria of novelty, non-obviousness, and the inventive step. This panel will examine the complexities of these fundamental patent requirements in practice, with a special focus on polymorph patents and related areas. We'll explore how recent developments and legal decisions impact innovators and the IP landscape. 

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
8 May 2026   LSIPR's senior reporter Marisa Woutersen speaks with Mythili Markowski of Regeneron on why new USPTO guidance is putting post-grant proceedings under the spotlight and how in-house teams are responding.
Americas
4 May 2026   LSIPR's senior reporter Marisa Woutersen speaks with Ben Doranz of Integral Molecular, fresh from the stage at LSPN Boston after speaking at a panel session on challenges in antibody patent protection.
Americas
1 May 2026   The Office of the US Trade Representative has placed the EU on its Watch List, outlining concerns about pharma legislation, GIs and digital copyright.